584 related articles for article (PubMed ID: 17277036)
21. Islet enhancer vildagliptin: a powerful partner with metformin for the treatment of patients with type 2 diabetes.
Scherbaum WA
Diabetes Obes Metab; 2009 May; 11 Suppl 2():1-2. PubMed ID: 19385977
[No Abstract] [Full Text] [Related]
22. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
23. Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan.
Hanif W; Malik W; Hassanein M; Kamal A; Geransar P; Andrews C; Azam M; Barnett AH
Curr Med Res Opin; 2013 Jul; 29(7):807-11. PubMed ID: 23659561
[TBL] [Abstract][Full Text] [Related]
24. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
Garber AJ; Schweizer A; Baron MA; Rochotte E; Dejager S
Diabetes Obes Metab; 2007 Mar; 9(2):166-74. PubMed ID: 17300592
[TBL] [Abstract][Full Text] [Related]
25. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
Filozof C; Gautier JF
Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
[TBL] [Abstract][Full Text] [Related]
26. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
[TBL] [Abstract][Full Text] [Related]
27. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.
Garber AJ; Foley JE; Banerji MA; Ebeling P; Gudbjörnsdottir S; Camisasca RP; Couturier A; Baron MA
Diabetes Obes Metab; 2008 Nov; 10(11):1047-56. PubMed ID: 18284434
[TBL] [Abstract][Full Text] [Related]
28. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
Del Prato S
Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
[TBL] [Abstract][Full Text] [Related]
29. Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus.
Yang W; Xing X; Lv X; Li Y; Ma J; Yuan G; Sun F; Wang W; Woloschak M; Lukashevich V; Kozlovski P; Kothny W;
J Diabetes; 2015 Mar; 7(2):174-81. PubMed ID: 24823599
[TBL] [Abstract][Full Text] [Related]
30. Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus.
Ning G; Wang W; Li L; Ma J; Lv X; Yang M; Wang W; Woloschak M; Lukashevich V; Kothny W
J Diabetes; 2016 May; 8(3):345-53. PubMed ID: 25929739
[TBL] [Abstract][Full Text] [Related]
31. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin.
Bolli G; Dotta F; Colin L; Minic B; Goodman M
Diabetes Obes Metab; 2009 Jun; 11(6):589-95. PubMed ID: 19515179
[TBL] [Abstract][Full Text] [Related]
32. Effects of vildagliptin versus saxagliptin on daily acute glucose fluctuations in Chinese patients with T2DM inadequately controlled with a combination of metformin and sulfonylurea.
Xiaoyan C; Jing W; Xiaochun H; Yuyu T; Shunyou D; Yingyu F
Curr Med Res Opin; 2016 Jun; 32(6):1131-6. PubMed ID: 26950829
[TBL] [Abstract][Full Text] [Related]
33. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment.
Kothny W; Shao Q; Groop PH; Lukashevich V
Diabetes Obes Metab; 2012 Nov; 14(11):1032-9. PubMed ID: 22690943
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
Cai L; Cai Y; Lu ZJ; Zhang Y; Liu P
J Clin Pharm Ther; 2012 Aug; 37(4):386-98. PubMed ID: 22191695
[TBL] [Abstract][Full Text] [Related]
35. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
[TBL] [Abstract][Full Text] [Related]
36. Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus.
Guarino E; Nigi L; Patti A; Fondelli C; Dotta F
Expert Opin Pharmacother; 2012 Jun; 13(9):1377-84. PubMed ID: 22397507
[TBL] [Abstract][Full Text] [Related]
37. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.
Kim D; MacConell L; Zhuang D; Kothare PA; Trautmann M; Fineman M; Taylor K
Diabetes Care; 2007 Jun; 30(6):1487-93. PubMed ID: 17353504
[TBL] [Abstract][Full Text] [Related]
38. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy.
Pratley RE; Rosenstock J; Pi-Sunyer FX; Banerji MA; Schweizer A; Couturier A; Dejager S
Diabetes Care; 2007 Dec; 30(12):3017-22. PubMed ID: 17878242
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin uptitration in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy: a randomized, open-label, prospective study (VISION).
Ji LN; Pan CY; Lu JM; Li H; Zhu DL; Li Q; Li QF; Peng YD; Tian HM; Yao C; Zhao ZG; Wang L; Wang BH;
Diabetes Obes Metab; 2016 Aug; 18(8):775-82. PubMed ID: 27406394
[TBL] [Abstract][Full Text] [Related]
40. Role of vildagliptin in managing type 2 diabetes mellitus in the elderly.
Halimi S; Raccah D; Schweizer A; Dejager S
Curr Med Res Opin; 2010 Jul; 26(7):1647-56. PubMed ID: 20441397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
